causal
PBMs block cheaper biosimilars to protect rebate revenue
PBMs keep high-cost drugs on formulary and exclude cheaper biosimilars because they earn rebates on the expensive drug but not the cheaper alternative — for example Humira at $8,000/month pre-rebate (3-6k after rebate) versus the biosimilar Yusimry at $594, which the big three PBMs won't allow because there's no rebate, so they make more money keeping patients on the costly drug.
causalpending
Speaker
Mark CubanEvidence Quote
“Humira, the pre-rebate price is about $8,000 per month. After rebates... it'll be anywhere from three to $6,000 a month. You can go to get your doctor to prescribe that biosimilar Yusimry and you pay $594.”
Created: 6/13/2026, 3:37:54 AM
Your notes
Loading notes...